Trial Profile
A Phase I, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2020
Price :
$35
*
At a glance
- Drugs Nesolicaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Proteostasis Therapeutics
- 24 Mar 2020 Status changed from recruiting to completed.
- 13 Apr 2018 Planned End Date changed from 1 Nov 2017 to 1 Dec 2018.
- 13 Apr 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2018.